Asian Spectator

Men's Weekly

.

AweMed Series Sponsors Eczema Family Day 2025 to Support Singapore’s Sensitive Skin Community

SINGAPORE - Media OutReach Newswire - 3 July 2025 - AweMed®, a skincare brand developed in collaboration with local dermatologists and paediatricians, sponsored the Eczema Family Day 2025—a...

Samsonite Unveils Sustainable ‘Magnum Eco’ Luggage Collection

HONG KONG SAR - Media OutReach - 21 April 2021 - On Earth Day (April 22), Samsonite is launching Magnum Eco − a durable, lightweight luggage collection that harnesses the innovative ...

Ganapati PLC Teams Up With Usain Bolt

LONDON, January 15, 2020 /PRNewswire-AsiaNet/ -- -International iGaming company, Ganapati PLC, has announced a partnership with the world's fastest man, Usain Bolt-The partnership will see t...

Celebrate Lunar New Year with iShopChangi’s Exclusive Discounts and Promotions

iShopChangi's exclusive discounts and promotions ensure everyone has something to smile about this Lunar New Year, with up to 58% off more than 6,500 products. Running until February 14, 202...

TOTALTEC Oilfield Services Limited Successfully Completed Its ...

SEVENOAKS, England, April 4, 2018 /PRNewswire-AsiaNet/ -- On 28th Feb 2018, TOTALTEC Oilfield Services Limited ("TOTALTEC" or the "Company") successfully completed its second equity finance ...

XTransfer Celebrating One-Year Anniversary in Hong Kong

Establishing a Strong Presence and Participating in Hong Kong "Global Sources Consumer Electronics ShowHONG KONG SAR - Media OutReach Newswire - 11 April 2024 - XTransfer, the World's Lead...

ChannelAdvisor Announces Integration with Kogan.com Marketplace

MELBOURNE, Australia, May 14, 2020 /PRNewswire-AsiaNet/ -- - Leading e-commerce solution provider offers brands and retailers potential access to millions of active Kogan.com customersChanne...

Wholesale Investor to Host Venture and Capital Conference 2021

SYDNEY, Sept. 10, 2021 /PRNewswire-AsiaNet/ -- Focuses on transformative technology platforms in Renewable Energy, Digital Assets, Agritech, Fintech, and Healthcare Event Highlights-Wholesal...

OPPO Launches Find X8 Series Globally, Marking Steady Progress in Globalization

OPPO Find X8 and Find X8 Pro launched in global markets Overseas markets have become the growth engine for OPPO, contributing approximately 60% of its total shipments OPPO...

Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan

Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan

TOKYO, Jul 6, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO? 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020. Eisai received marketing and manufacturing approval for this formulation on January 23, 2020, and the product was added to Japan?s National health Insurance drug price list on April 22, 2020.

Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan

DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.

The approval of DAYVIGO in Japan is based on findings from two pivotal Phase III studies(1),(2) (SUNRISE 1 and SUNRISE 2) in adult patients with insomnia, as well as evaluation of residual effects including the middle of the night waking, next morning postural stability (falling prediction indicator), and memory through Studies 1063 and 1084.

The SUNRISE 11 clinical trial conducted in North America and Europe utilized objective assessment with overnight measurement through polysomnography, and confirmed statistically significant shortening or improvement of sleep onset latency (primary objective) as well as sleep efficiency and wake after sleep onset (secondary objectives) with DAYVIGO compared to tartrate-sustained-release drug zolpidem (6.25 mg, not yet approved in Japan) and placebo.

The SUNRISE 22 clinical trial, conducted globally including in Japan, evaluated patients subjectively through sleep diaries and confirmed statistically significant improvement in sleep onset latency (primary objective) as well as subjective sleep efficiency and subjective wake after sleep onset (secondary objectives) compared to placebo. Main side effects of DAYVIGO as observed in the two trials were somnolence, headache, dizziness, and fatigue.

Analyses in both studies suggested DAYVIGO was not associated with rebound insomnia, and there was no evidence of withdrawal effects following treatment discontinuation, suggesting it does not produce physical dependence in those taking it for up to one year.In a special safety study (Study 106)(3), DAYVIGO at 5 mg and 10 mg doses did not cause statistically significant impairment in the next morning driving performance in healthy adult or elderly subjects (compared with placebo). Additional special safety studies (Study 108)(4) evaluated middle-of-the-night safety, next morning postural stability, and memory. The effects of DAYVIGO on next day postural stability and memory were evaluated in two randomized, placebo and active-controlled trials. There were no meaningful differences between DAYVIGO and placebo on next-day postural stability or memory at either dose. While there is a need for caution regarding the potential for middle-of-the-night postural instability as well as attention and memory impairment, no problem-signifying degradation was observed between DAYVIGO- and placebo-administered groups.

In June 2020, DAYVIGO was launched in the U.S. for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. In addition, Eisai submitted a new drug application seeking approval of DAYVIGO in Canada and Australia.

Insomnia is characterized by difficulty falling asleep, staying asleep, or both, despite an adequate opportunity to sleep, which can lead to daytime consequences, such as fatigue, difficulty concentrating, and irritability.(5),(6) Insomnia is one of the most common sleep-wake disorders. Approximately 30% of adults worldwide have symptoms of insomnia.(7),(8) In particular, older adults tend to have a higher prevalence rate with many experiencing insomnia symptoms for months to years. As a result, insomnia causes various social losses, such as long absences and reduced productivity. It can increase the risk of falling in older adults.(9)

Through the launch of DAYVIGO, Eisai will continue to prioritize the provision of appropriate usage and safety information. By providing DAYVIGO as a new option for the treatment of insomnia, Eisai aims for contribution to the restoration of daytime function and recovery for patients with insomnia by delivering an active daytime life through fast sleep onset and good quality sleep.

For more information visit https://www.eisai.com/news/2020/pdf/enews202036pdf.pdf.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Terjebak budaya sungkan: Enggan komplain bisa menghambat perbaikan pelayanan publik

Sejumlah orang sedang menunggu antrean di ruangan di suatu fasilitas pelayanan publik di Jakarta. Zulkarnain.B/Shutterstock● Masih banyak masyarakat enggan komplain karena budaya sungkan dan tid...

Kamu nyaman curhat dengan AI? Hati-hati kena gangguan mental

Seorang perempuan sedang duduk sambil curhat dengan robot humanoid AI di sebuah ruang tamu.VesnaArt/Shutterstock● Kaum muda kini sering menjadikan ‘chatbot’ AI sebagai teman curhat.&...

Cemas saat berulang tahun? Simak tip psikolog untuk hadapi ‘birthday blues’

DavideAngelini/ShutterstockUlang tahun biasanya jadi momen membahagiakan penuh dengan tawa, perayaan, dan hadiah. Namun, tak jarang menjelang ulang tahun, kita justru merasa sedih.Ulang tahun dapat me...